Homecare Homebase revealed over 4 million patients are denied home health services annually, highlighting critical access issues and the impact of proposed Medicare cuts.

Fluid resolution at week 4 seems to translate into longer dosing intervals at week 96 of the PULSAR trial that assessed Eylea ...

Ixo-vec reduced anti-VEGF injection frequency and was well tolerated in patients with wet AMD. A phase 3 pivotal trial ...

IRX-101, a new antiseptic tested in patients receiving eye injections for macular degeneration, resulted in less pain and ...

Small doses of the involuntary nervous system blocker, atropine, may offer a non-invasive treatment for symptomatic vitreous ...

The FDA has approved VIZZ, a once-daily, preservative-free eye drop that improves near vision in adults with presbyopia for up to 10 hours.

Most of the attention has been on Medicaid cuts, but the reconciliation bill and CMS rule changes will also slash enrollment ...

Results show dosing intervals increasing by two weeks or longer for patients with diabetic macular edema and neovascular (wet) age-related macular degeneration who switch to Eylea HD.

In a study in mice, a wireless implant was able to release glucagon as an emergency treatment for hypoglycemia, a serious ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

Anti-VEGF and anti-complement therapies work on distinct mechanisms in age-related macular degeneration, and both may be ...

Data shared by Schneider showed that 45% of those originally assigned to the Eylea HD groups had completed dosing intervals of 20 weeks or more. At the end of the 156-week trial, 28% had an assigned ...